TRINALIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRINALIN (TRINALIN).
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
| Metabolism | Azatadine is extensively metabolized in the liver via hydroxylation and glucuronidation; pseudoephedrine is partially metabolized in the liver by N-demethylation (CYP450) and excreted largely unchanged in urine. |
| Excretion | Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% |
| Half-life | Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect |
| Protein binding | 70-80% bound, primarily to albumin |
| Volume of Distribution | Approximately 6-8 L/kg; indicates extensive tissue distribution with high affinity for nasal mucosa and respiratory tissues |
| Bioavailability | Oral: 80-90% (high first-pass metabolism minimal) |
| Onset of Action | Oral: 30-60 minutes |
| Duration of Action | Oral: 12-24 hours; clinical note: duration supports twice-daily dosing; may extend up to 24 hours in some patients |
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific guidelines available. Use caution in patients with renal impairment due to potential accumulation of pseudoephedrine. Avoid in severe renal impairment (CrCl <30 mL/min) if possible. |
| Liver impairment | No specific guidelines available. Use caution in severe hepatic impairment due to potential altered metabolism of azatadine and pseudoephedrine. |
| Pediatric use | Not recommended for use in children under 12 years of age. For children 12 years and older, same as adult dosing: one tablet orally every 12 hours. |
| Geriatric use | Use with caution due to increased sensitivity to anticholinergic effects (azatadine) and sympathomimetic effects (pseudoephedrine). Consider starting at lower doses or extended dosing intervals. Avoid use in elderly patients with hypertension, heart disease, or prostatic hyperplasia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRINALIN (TRINALIN).
| Breastfeeding | Both components are excreted in breast milk. Pseudoephedrine M/P ratio is approximately 2.6 (higher in acidic milk). Azatadine may suppress lactation. Avoid use in breastfeeding due to potential irritability and sleep disturbance in infants. |
| Teratogenic Risk | TRINALIN (azatadine/pseudoephedrine) is pregnancy category B. Animal studies have not demonstrated fetal risk, but adequate human studies are lacking. Use only if clearly needed. First trimester: potential risk not excluded; second and third trimesters: no known teratogenic effects, but pseudoephedrine may reduce uteroplacental blood flow. |
■ FDA Black Box Warning
No FDA black box warning exists for TRINALIN.
| Serious Effects |
["Severe hypertension","Coronary artery disease","MAOI therapy within 14 days","Narrow-angle glaucoma","Urinary retention","Severe renal impairment","Hypersensitivity to any component"]
| Precautions | ["Cardiovascular effects: hypertension, palpitations, arrhythmias","CNS stimulation: insomnia, nervousness, dizziness","Angle-closure glaucoma risk","Urinary retention in patients with prostatic hypertrophy","Increased intraocular pressure","Thyrotoxicosis","Elderly patients more sensitive to anticholinergic effects"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and fetal growth (ultrasound) if used chronically. Assess for signs of reduced placental perfusion (e.g., fetal distress, growth restriction). |
| Fertility Effects | No specific data on azatadine/pseudoephedrine. Pseudoephedrine may affect uterine contractility. No evidence of permanent fertility impairment. |